Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: Results from a pilot trial

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2141-2147

  Nand, Sucha ^a   Godwin, John ^a   Smith, Scott ^a   Barton, Kevin ^a   Michaelis, Laura ^a   Alkan, Serhan ^a   Veerappan, Ranjitha ^a   Rychlik, Karen ^a   Germano, Eliza ^a   Stiff, Patrick ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Azacitidine; Gemtuzumab ozogamicin

Indexed keywords

AZACITIDINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; CANCER REGRESSION; CANCER STAGING; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ELDERLY CARE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOOT EDEMA; HEMATURIA; HUMAN; INJECTION SITE PAIN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LOW DRUG DOSE; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RIGOR; SKIN REDNESS; SURVIVAL TIME; TYPHLITIS;

AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DRUG TOXICITY; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 57049171822     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802451254     Document Type: Article

References (21)

1. Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L. Godwin, J. E. et al. (2006) Age and acute myeloid leukemia. Blood, 107, pp. 3481-3485.
2. Lowenberg, B., Downing, J. R. and Burnett, A. (1999) Acute myeloid leukemia. N Engl J Med, 341, pp. 1051-1062.
3. Chauncey, T. R. (2001) Drug resistance mechanisms in acute leukemia. Curr Opin Oncol, 13, pp. 21-26.
4. Leith, C. P., Kopecky, K. J. Chen, IM, McConnell T, Slovak ML, Head DR et al. (1998) Acute myeloid leukemia in the elderly: A biologically distinct disease in which MDR1 expression and unfavorable cytogenetics contribute to a poor clinical response. Studies of the Southwest Oncology Group. Acute leukemia VII-experimental approaches and novel therapies. pp. 413-421. Springer-Verlag, Heidelberg
5. Willman, C. L. (1997) The prognostic significance of the expression and function of genes mediating multi-drug resistance in adult patients with acute myeloid leukemia: Biologic and clinical studies of the Southwest oncology Group leukemia research program. Semin Hematol, 34, pp. 25-33.
6. Goldstone, A. H., Burnett, A. K., Wheatley, K. and Smith, AG, Hutchinson RM, Clark RE (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in elderly patients: The results of United Kingdom Medical Research Council AML 11 trial. Blood, 98, pp. 1302-1311.
7. Hiddeman, W., Kern, W., Schoch, C., Fonatsch, C., Heinecke, A. Wormann, B. et al. (1999) Management of acute myeloid leukemia in the elderly patients. J Clin Oncol, 17, pp. 3569-3576.
8. Godwin, J. E., Kopecky, K. J. Head, DR, Willman CL, Leith CP, Hynes HE et al. (1998) A double-blind placebo controlled trial of granulocyte colony stimulation factor in the elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031). Blood, 91, pp. 3607-3615.
9. Rowe, J. M., Neuberg, D. Friedenberg, W, Bennett JM, Paietla E, Makary AZ et al. (2004) A Phase 3 study of three induction regimens and of priming with GM-CSF in older patients with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood, 103, pp. 479-485.
10. Sikic, B. I. (1993) Modulation of multidrug resistance: At the threshold. J Clin Oncol, 11, pp. 1629-1635.
11. Chauncey, T. R., Rankin, A. Anderson, JE, Chen I, Kopecky KJ, Godwin JC et al. (2000) A Phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia using mitoxantrone, etoposide and the MDR modulator PSC 833: A Southwest Oncology Group study 9617. Leuk Res, 24, pp. 567-574.
12. Knipp, H., Hildebrandt, B. Giagounidis, A, Kobbe G, Haas R, Aul C et al. (2004) Intensive chemotherapy is not recommended for patients with acute myeloid leukemia or high-risk myelodysplastic syndromes aged over 60 years with complex karyotype abnormalities. Blood, 104, p. 24a.
13. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P. Sanz, G. et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, pp. 2079-2088.
14. Fenaux, P., Mufti, G. J., Santini, V., Finelli, C., Giagounidis, A. Schoch, R. et al. (2007) Azacitidine (AZA) treatment prolongs overall survival (OS) in higher risk MDS patients compared to conventional care regimens (CCR). Blood, 110, p. 250a.
15. Silverman, L. R., McKenzie, D. R. Peterson, BL, Stone RM, Powell BR, Mayo C et al. (2005) Response rates in patients with acute myeloid leukemia (AML) treated with azacytidine using WHO and International Working Group (IWG) criteria for myelodysplastic syndrome. Blood, p. 106.
16. Larson, R. A., Boogaerts, M. Estey, E. et al. (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 16, pp. 1627-1636.
17. Linenberger, M. L., Hong, T. Flowers, D, Sievers EL, Gooley TA, Bennett JM et al. (2001) Multidrug-resistance phenotype and clinical response to gemtuzumab ozogamicin. Blood, 98, pp. 988-994.
18. Walter, R. B., Gooley, T. A., van der Velden, V HJ, Loken, M. R., van Dongen, J JM Flowers, D. A. et al. (2007) CD33 expression and P-glycoprotein mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood, 109, pp. 4168-4170.
19. van der Velden, V HJ, te Marvelde, J G Hoogeveen, PG, Bernstein ID, Houstmuller AB, Berger MS et al. (2001) Targeting of the CD33-calicheamicin immunoconjugate mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97, pp. 3197-3204.
20. van der Velden, V HJ, Boeckx, N. Jedema, I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al. (2004) High CD33 antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia. Leukemia, 18, pp. 983-988.
21. Yang, As, Doshi, K. D. Choi, SW, Mason JB, Mannari RK et al. (2006) DNA methylation changes after decitabine therapy in patients with leukemia. Cancer Res, 66, pp. 5495-5503.